SWRP
MRNA icon

Summit Wealth & Retirement Planning’s Moderna MRNA Stock Holding History

Summit Wealth & Retirement Planning’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,118
Closed -$325K – 88
2023
Q1 		$325K Sell
2,118
-1,444
-41% -$238K 0.12% 77
2022
Q4 		$640K Sell
3,562
-23
-0.6% -$3.76K 0.26% 50
2022
Q3 		$424K Sell
3,585
-10
-0.3% -$1.52K 0.17% 71
2022
Q2 		$514K Sell
3,595
-34
-0.9% -$4.86K 0.2% 67
2022
Q1 		$625K Buy
3,629
+1,785
+97% +$301K 0.22% 60
2021
Q4 		$468K Buy
+1,844
New +$539K 0.16% 63
2020
Q4 		– Sell
-3,006
Closed -$213K – 114
2020
Q3 		$213K Sell
3,006
-7,338
-71% -$512K 0.09% 101
2020
Q2 		$664K Sell
10,344
-7,231
-41% -$396K 0.31% 60
2020
Q1 		$526K Buy
+17,575
New +$404K 0.28% 67

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Summit Wealth & Retirement Planning's MRNA Position: Q2 2023 in Review

Summit Wealth & Retirement Planning sold out of Moderna (MRNA) in Q2 2023, closing a stake of 2,118 shares — an estimated $325K sold.

Summit Wealth & Retirement Planning first reported a position in MRNA in Q1 2020 and held it in 9 quarters. The position peaked at $664K in Q2 2020. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Summit Wealth & Retirement Planning reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Summit Wealth & Retirement Planning sold 2,118 Moderna shares in Q2 2023, an estimated $325K.
  • Summit Wealth & Retirement Planning first reported a position in Moderna in Q1 2020 and held it in 9 quarters.
  • Summit Wealth & Retirement Planning's Moderna position peaked at $664K in Q2 2020.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Summit Wealth & Retirement Planning's 13F filing for Q2 2023, filed 26 Jul 2023.